These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36723856)

  • 1. Multimodality Therapies for Localized Prostate Cancer.
    Valle LF; Jiang T; Weiner AB; Reiter RE; Rettig MB; Shen J; Chang AJ; Nickols NG; Steinberg ML; Kishan AU
    Curr Oncol Rep; 2023 Mar; 25(3):221-229. PubMed ID: 36723856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
    Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
    JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selecting the optimal radiation modality in prostate cancer.
    Valle LF; Kishan AU; Franco A; Ma TM; Nikitas J; Farrell M; Chang AJ; Nickols NG; Steinberg ML
    Clin Adv Hematol Oncol; 2023 Sep; 21(9):494-501. PubMed ID: 37647496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
    Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
    Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer.
    Nikitas J; Kishan A; Chang A; Duriseti S; Nichols NG; Reiter R; Rettig M; Brisbane W; Steinberg ML; Valle L
    World J Urol; 2024 Mar; 42(1):165. PubMed ID: 38492111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis.
    Greenberger BA; Zaorsky NG; Den RB
    Eur Urol Focus; 2020 Mar; 6(2):404-418. PubMed ID: 31813810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer.
    Herlemann A; Cowan JE; Washington SL; Wong AC; Broering JM; Carroll PR; Cooperberg MR
    Eur Urol; 2024 Jun; 85(6):565-573. PubMed ID: 37858454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer.
    Sebastian NT; McElroy JP; Martin DD; Sundi D; Diaz DA
    Urol Oncol; 2019 Nov; 37(11):813.e11-813.e19. PubMed ID: 31109836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
    Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
    Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.
    Berlin A; Moraes FY; Sanmamed N; Glicksman R; Koven A; Espin-Garcia O; Leite ETT; Silva JLF; Gadia R; Nesbitt M; Catton CN; Kaffenberger S; Salami SS; Morgan TM; Hearn JWD; Jackson WC; Mehra R; Chung P; Fleshner NE; Zumsteg ZS; Dess RT; Feng FY; Finelli A; Spratt DE
    J Urol; 2019 Feb; 201(2):284-291. PubMed ID: 30153435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Outcomes After Localized Prostate Cancer Treatment.
    Al Hussein Al Awamlh B; Wallis CJD; Penson DF; Huang LC; Zhao Z; Conwill R; Talwar R; Morgans AK; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; O'Neil BB; Koyama T; Hoffman KE; Barocas DA
    JAMA; 2024 Jan; 331(4):302-317. PubMed ID: 38261043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
    Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
    J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailored treatment including radical prostatectomy and radiation therapy + androgen deprivation therapy versus exclusive radical prostatectomy in high-risk prostate cancer patients: results from a prospective study.
    Castelli T; Russo GI; Favilla V; Urzi D; Spitaleri F; Reale G; Giardina R; Saita A; Madonia M; Cimino S; Morgia G
    Int Braz J Urol; 2014; 40(3):322-9. PubMed ID: 25010298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.
    Tosco L; Briganti A; D'amico AV; Eastham J; Eisenberger M; Gleave M; Haustermans K; Logothetis CJ; Saad F; Sweeney C; Taplin ME; Fizazi K
    Eur Urol; 2019 Jan; 75(1):44-60. PubMed ID: 30286948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
    Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
    Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
    Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term oncologic outcomes of radical prostatectomy compared with brachytherapy-based approaches for intermediate- and high-risk prostate cancer.
    Crook J
    Brachytherapy; 2015; 14(2):142-7. PubMed ID: 25255713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.